Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
1. A method for treating Hunter syndrome in a subject in need thereof, the method comprising administering to said subject a composition comprising the effective amount of a recombinant iduronate-2-sulfatase (IDS) having the amino acid sequence of SEQ ID NO: 1, wherein a cysteine residue at position 59 in the IDS amino acid sequence in the composition is converted into formylglycine (FGly) at a molar ratio of 65% or higher.
2. The method of claim 1 , wherein the cysteine residue at position 59 in the recombinant IDS amino acid sequence is converted into FGly at a molar ratio of 75% or higher.
3. The method of claim 1 , wherein the cysteine residue at position 59 in the recombinant IDS amino acid sequence is converted into FGly at a molar ratio of 80% or higher.
4. The method of claim 1 , wherein the recombinant IDS contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS.
5. The method of claim 4 , wherein the recombinant IDS contains mannose-6-phosphate in an amount of 2.5 to 3.0 moles per mole of IDS.
6. The method of claim 1 , wherein the composition is suitable for injection, oral administration, or parenteral administration.
7. A method for treating Hunter syndrome in a subject in need thereof, the method comprising administering to said subject an injectable formulation comprising a recombinant iduronate-2-sulfatase (IDS) at a dose of 0.5-1 mg IDS/kg body weight, said recombinant IDS having the amino acid sequence of SEQ ID NO: 1, wherein a cysteine residue at position 59 in the IDS amino acid sequence is converted into formylglycine (FGly) at a molar ratio of 65% or higher.
8. The method of claim 7 , wherein the cysteine residue at position 59 in the recombinant IDS amino acid sequence is converted into FGly at a molar ratio of 75% or higher.
9. The method of claim 7 , wherein the cysteine residue at position 59 in the recombinant IDS amino acid sequence is converted into FGly at a molar ratio of 80% or higher.
10. The method of claim 7 , wherein the dose is about 0.5 mg IDS/kg body weight.
11. The method of claim 7 , wherein the dose is about 1 mg IDS/kg body weight.
12. The method of claim 7 , wherein the formulation is administered intravenously.
13. The method of claim 7 , wherein the formulation is administered subcutaneously.
14. The method of claim 1 , wherein the effective amount of the IDS is 0.5 mg IDS/kg body weight.
15. The method of claim 1 , wherein the effective amount of the IDS is 1.0 mg IDS/kg body weight.
16. The method of claim 7 , wherein the recombinant IDS contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS.
17. The method of claim 16 , wherein the recombinant IDS contains mannose-6-phosphate in an amount of 2.5 to 3.0 moles per mole of IDS.